Long-term Impact of NMDAR Encephalitis, Level 3

Recruiting Observational Study
NMDAR Autoimmune Encephalitis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
30 (estimated)
Sponsor
Hospices Civils de Lyon · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year. Patients with anti-NMDAR encephalitis experience an acute phase of the disease characterized by psychosis, memory loss, seizures, autonomic nervous system instability, or coma. Since the discovery of this disease 14 years ago by…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients with NMDAR encephalitis * Age ≥ 18 years old * Patient affiliated to a social security system * No opposition from the patient * Access to an internet connection and a computer Exclusion Criteria: * Patients whithout NMDAR encephalitis * Patient under guardianship o…
Contacts

Jérôme HONNORAT, Pr

0472357806

jerome.honnorat@chu-lyon.fr

CONTACT

Chloé BUTTARD

0426739377

ext-chloe.buttard@chu-lyon.fr

CONTACT